Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Neoplasm Female Metastatic Breast Cancer Patients with stage IV breast cancer with metastases demonstrated by appropriate imaging techniques (computer tomography CT, positron emission tomography PET or PET/CT, MRI, ultrasound, etc.) 2. Histologically or cytologically confirmed tumor 3. Age of 18 years or more 4. ECOG performance status of 0 5. Patients have failed, untolerated or refused standard therapeutic modalities 6. Not received systemic anticancer therapy or radiation or had major surgery in last 2 weeks 7. Not currently participating in another study 8. Anticipated survival of at least 2 months 9. Baseline AST and ALT not greater than 2.5 X upper institutional limit 10. Serum copper within normal limits 11. Serum ceruloplasmin > 17 mg/dL 12. Able and willing to sign informed consent and to comply with study procedures 13. Able to ingest oral medications 14. No known allergy to disulfiram or copper 15. Willing to refrain from ingestion of alcoholic beverages while on the study  Participation in another clinical trial of a therapeutic drug during the past 14 days 2. Addiction to alcohol or drugs 3. Baseline AST or ALT greater than 2.5 X upper institutional limit 4. Unable to ingest oral medications 5. Unable to undergo CT/SPECT scanning because of inability to lie recumbent in the scanner 6. Actively receiving cytotoxic cancer chemotherapy agents 7. Anticipated survival of less than 2 months 8. Women of child-bearing potential who are not using a commonly accepted effective means of contraception; women of child-bearing potential will have negative pregnancy test before enrollment 9. History of active liver disease, including chronic active hepatitis, viral hepatitis (hepatitis B, C and CMV), cholestatic jaundice of any etiology, toxic hepatitis, or cholestatic hepatitis or jaundice with bilirubin greater than 2.0 X upper institutional limit 10. History of Wilson's disease or family member with Wilson's disease 11. History of hemochromatosis or family member with hemochromatosis 12. History of other iron overload syndrome such as hemochromatosis 13. Need for metronidazole, warfarin and/or theophylline medication, the metabolism of which is likely influenced by disulfiram 14. Pregnant women and nursing mothers are not allowed to enroll on this study 15. Patients who are taking medications metabolized by cytochrome P450 2E1, including chlorzoxazone or halothane and its derivatives